Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EAA-090

Known as: EAA 090, Perzinfotel 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
OBJECTIVE To investigate the ability of perzinfotel (an N-methyl-d-aspartate receptor antagonist) and a proprietary phospholipase… Expand
2010
2010
OBJECTIVE To determine the effects of perzinfotel, butorphanol, and their combination on the minimal alveolar concentration (MAC… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2009
2009
OBJECTIVE-To determine the effects of IV administration of perzinfotel and a perzinfotel-fentanyl combination on the minimum… Expand
  • table 1
  • table 2
2009
2009
Previous studies with perzinfotel (1), a potent, selective, competitive NMDA receptor antagonist, showed it to be efficacious in… Expand
  • figure 1
  • table 2
  • figure 2
  • table 3
  • figure 3
2007
2007
OBJECTIVE To determine the effect of IV administration of perzinfotel on the minimum alveolar concentration (MAC) of isoflurane… Expand
2005
2005
Perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] is a selective, competitive N… Expand
2005
2005
Perfusion of acute hippocampal slices with stimulatory buffers has long been known to induce rhythmic, large amplitude… Expand
2004
2004
Two novel N-methyl-d-aspartate (NMDA) antagonists with unique chemical structures, EAA-090 (2-[8,9-dioxo-2, 6-diazabicyclo[5.2.0… Expand
2002
2002
EAA-090 is a novel squaric acid amide derivative that has been identified as a potential treatment for the ischemic brain damage… Expand
1998
1998
The diazabicyclic amino acid phosphonate 15, [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid, was… Expand